Ideas to Impact
Absci is unlocking the potential of next-generation biologics by harnessing deep learning AI and synthetic biology to explore a vast therapeutic sequence space inaccessible to conventional discovery methods.
We started with a question: What if there was a better way to create new medicines?
From a basement in Portland, we engineered E. coli, biopharma’s original host organism, to be an effective factory for complex human proteins. But we didn’t stop there.
We built our technology to enable better, faster, smarter biologic drug discovery and cell line development. We call it Integrated Drug Creation™.
Get to know us.
Sean McClain
Founder, CEO & Director
Matthew Weinstock, PhD
Chief Technology Officer
Greg Schiffman, CPA
Chief Financial Officer
Sarah Korman, PhD, JD
Chief Legal Officer
Denise Dettore
Chief People Officer
Jack Gold
Chief Marketing Officer
Penelope
Chief Morale Officer
Todd Bedrick, CPA
SVP, Chief Accounting Officer
Deniz Kural, PhD
SVP, Antibody & Target Discovery
James Sietstra
SVP, Business Development
Jonathan Eads, MS
SVP, Informatics
Jens Plassmeier, PhD
SVP, Synthetic Biology R&D
Thomas Wrona, PhD, JD
SVP, Intellectual Property
Kate Corcoran, PhD
VP, Investor Relations
Imad Ajjawi, PhD, MBA
VP, Business Development
Daniele Biasci, PhD
Consulting VP, Immunology
Explore current openings and get ready to prove that impossible isn’t.
Join us